Streetbeat News

CTNM

Contineum Therapeutics Inc.

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

13.68

Mkt cap

362M

Volume

171K

High

14.04

P/E Ratio

-38.97

52-wk high

22.00

Low

12.95

Div yield

N/A

52-wk low

12.33

UnitedHealth Group Incorporated (NYSE:UNH) reported better-than-expected first-quarter earnings, with adjusted EPS of $6.91 and revenues of $99.8 billion, causing its shares to surge 6.2%. Other stocks also moved significantly, including Macatawa Bank Corporation (NASDAQ:MCBC) which jumped 38.8% after announcing a merger with Wintrust Financial Corporation (NASDAQ:WFTC), and several others like Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), Cullinan Oncology, Inc. (NASDAQ:CGEM), and Telefonaktiebolaget LM Ericsson (NASDAQ:ERIC) reporting positive developments.

Portfolio Pulse from Avi Kapoor

April 16, 2024 | 2:15 pm

Trading for the IPO security CTNM was halted but has now resumed as of 10:10:00 AM ET.

Portfolio Pulse from Benzinga Newsdesk

April 05, 2024 | 2:10 pm

Contineum Therapeutics has priced its initial public offering (IPO) of 6,875,000 Class A common shares at $16 per share. This marks the company's entry into the public market.

Portfolio Pulse from Benzinga Newsdesk

April 05, 2024 | 6:17 am

Contineum Therapeutics, Inc (NASDAQ:CTNM) is set to begin trading on NASDAQ on April 05, with its IPO priced between $16.00 and $18.00 per share. The company, a clinical stage biopharmaceutical firm, focuses on developing therapies for NI&I indications with high unmet need. An insider lock-up period is set for 180 days, ending on October 02, 2024.

Portfolio Pulse from Benzinga Insights

April 04, 2024 | 3:00 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.